Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors

This publication has 15 references indexed in Scilit:

• Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patients
  Liver Transplantation, 2006
• 213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
  Clinical Cancer Research, 2006
• The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms
  Surgery, 2004
• Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors
  Molecular Imaging & Biology, 2003
• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
  European Journal of Nuclear Medicine and Molecular Imaging, 2003
• Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
  Seminars in Nuclear Medicine, 2002
• Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
  Seminars in Nuclear Medicine, 2002
• Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data
  European Journal of Nuclear Medicine and Molecular Imaging, 2001
• Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG)
  European Journal of Gastroenterology & Hepatology, 1999
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
  European Journal of Nuclear Medicine and Molecular Imaging, 1993